Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24742927 | 0.91 | HRH3 (0.41) | HRH3 | |
| SCHEMBL21871369 | 0.88 | HRH3 (0.40) | HRH3 | |
| SCHEMBL9963118 | 0.86 | HRH3 (0.38) | HRH3 | |
| SCHEMBL8121510 | 0.86 | HRH3 (0.38) | HRH3 | |
| SCHEMBL9963119 | 0.86 | HRH3 (0.38) | HRH3 | |
| SCHEMBL21673538 | 0.83 | HRH3 (0.37) | HRH3 | |
| SCHEMBL26501052 | 0.82 | HRH3 (0.44) | HRH3 | |
| SCHEMBL19102360 | 0.82 | HRH3 (0.36) | HRH3 | |
| SCHEMBL25670353 | 0.81 | HRH3 (0.41) | HRH3 | |
| SCHEMBL21016656 | 0.81 | HRH3 (0.34) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101573361-B | Aminopyrimidine derivatives as PLK1 inhibitors | MSD KK | 2012-05-30 | — | — | CN | claimed |
| CN-101573361-A | Novel aminopyrimidine derivative as plk1 inhibitor | BANYU PHARMA CO LTD (JP) | 2009-11-04 | — | — | CN | claimed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024020419-A1 | AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2008116185-A2 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-03-29 | — | — | US | disclosed |
| CN-1283626-C | Substituted benzene derivative or salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2006-11-08 | — | — | CN | disclosed |
| CN-1742013-A | Pyrazolopyrimidine compound and method for producing the same | TANABE SEIYAKU CO (JP) | 2006-03-01 | — | — | CN | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| CN-1656086-A | Benzofuran derivative | TANABE SEIYAKU CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| CN-1476433-A | Substituted benzene derivative or salt thereof | ֮����ҩ��ʽ���� | 2004-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | HRH3 335/4885 |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | HRH3 4356/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | HRH3 3415/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HRH3 387/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | HRH3 246/4885 |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | PHKG1, MAP3K19, MAP3K20 | HRH3 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.